Clear-cell Metastatic Renal Cell Carcinoma
Conditions
Brief summary
The purpose of this study is to assess whether certain metabonomics and/or lipidomics features in correlation with pharmacokinetics before, during and after treatment with sunitinib or pazopanib in first line can predict toxicity and efficacy of sunitinib or pazopanib in metastatic clear cell renal cell carcinoma patients.
Interventions
DRUGpatients with sunitinib or pazopanib
The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
Sponsors
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Woman or man ≥ 18 Years old, histologically proven metastatic clear cell (or al least clear cell predominant) RCC, * Good or intermediate risk according to MSKCC-criteria, Subjects falling into conditions for reimbursement of sunitinib or pazopanib in the context of mRCC, * Measurable disease based on RECIST criteria (version 1.1) , Subject has given voluntary written informed consent, * Subject is in the investigator's opinion, willing and able to comply with the protocol requirements, Subject has an ECOG ≤ 2, * Subject with a life expectancy ≥ 3 months, * Concurrent treatment with bisphosphonates and denosumab is allowed however it should have been started before screening of the study. If possible starting new medications between the baseline metabolo- and lipidomotype- and the first metabolo- and lipidomotypeanalysis should be avoided, * Subjects having recovered from side effects from previous therapies to a grade 1 CTC vs 4.0 criteria
Exclusion criteria
* Patients with non-clear cell RCC and/or with sarcomatoid differentiation, * Patients presenting any other type of cancer disease within 5 years from inclusion into this study; in the absence of cervical cancer or basocellular carcinoma, Patients with uncontrolled arterial hypertension, * Patients with uncontrolled hypo- or hyperthyroidism, * Patient had major surgery within 4 weeks before enrolment, * Patient with myocardial infarction within 6 months prior enrolment or with NHYA class III otr IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia or electrocardiographic evidence of acute ischemia or active conduction system abnormalities, * Patient has another serious medical condition that could potentially interfere with the completion of study, * Sero-positive for HIV, Subject known to be hepatitis B surface antigen positive or who has an active hepatitis C infection, * Subject has an active systemic infection requiring treatment, * Female subject is pregnant or breast feeding, Subject enrolled in another clinical trial and/or receiving an investigational agent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment assessment by using RECIST 1.1 and adverse events will be documented using the NCI-CTC coding system (version 4.0) | up to 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Identifying the level metabolotype and/or lipidomotype of metastatic clear cell renal cell carcinoma patients before starting sunitinib or pazopanib (in comparison with healthy volunteers) on blood and urine samples by biochemistry techniques | up to 5 years |
Countries
Belgium
Outcome results
None listed